Update on the development of lurasidone as a treatment for patients with acute schizophrenia

References

• Gold JM Cognitive deficits as treatment targets in schizophrenia Schizophr Res 2004 72 1 21 28 15531404
   PubMed Web of Science ®Google Scholar
• Green MF Kern RS Heaton RK Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr Res 2004 72 1 41 51 15531406
   PubMed Web of Science ®Google Scholar
• Elvevåg B Goldberg TE Cognitive impairment in schizophrenia is the core of the disorder Crit Rev Neurobiol 2000 14 1 1 21 11253953
   PubMed Web of Science ®Google Scholar
• Harvey PD When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry (Edgmont) 2009 6 7 12 14 19724764
   PubMedGoogle Scholar
• Lieberman JA Perkins D Belger A The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches Biol Psychiatry 2001 50 11 884 897 Erratum in:Biol Psychiatry 2002;51(4):346 11743943
   PubMed Web of Science ®Google Scholar
• Cannon TD Bearden CE Hollister JM Rosso IM Sanchez LE Hadley T Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study Schizophr Bull 2000 26 379 393 10885638
   PubMed Web of Science ®Google Scholar
• Jones P Rodgers B Murray R Marmot M Child development risk factors for adult schizophrenia in the British 1946 birth cohort Lancet 1994 344 1398 1402 7968076
   PubMed Web of Science ®Google Scholar
• Lencz T Smith C McLaughlin D Generalized and specific neurocognitive deficits in prodromal schizophrenia Biol Psychiatry 2006 59 863 871 16325151
   PubMed Web of Science ®Google Scholar
• McGlashan TH Hoffman RE Schizophrenia as a disorder of developmentally reduced synaptic connectivity Arch Gen Psychiatry 2000 57 637 648 10891034
   PubMed Web of Science ®Google Scholar
• Niendam TA Bearden CE Rosso IM A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings Am J Psychiatry 2003 160 2060 2062 14594759
   PubMed Web of Science ®Google Scholar
• Gold JM Is cognitive impairment in schizophrenia ready for diagnostic prime time? World Psychiatry 2008 7 32 33 18458780
   PubMed Web of Science ®Google Scholar
• Sawa A Snyder SH Schizophrenia: diverse approaches to a complex disease Science 2002 296 692 695 11976442
   PubMed Web of Science ®Google Scholar
• Weinberger DR Berman KF Zec RF Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence Arch Gen Psychiatry 1986 43 114 124 3947207
   PubMed Web of Science ®Google Scholar
• Ragland JD Laird AR Ranganath C Blumenfeld RS Gonzales SM Glahn DC Prefrontal activation deficits during episodic memory in schizophrenia Am J Psychiatry 2009 166 863 874 19411370
   PubMed Web of Science ®Google Scholar
• Harvey PD Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia Innov Clin Neurosci 2011 8 10 14 18 22132366
   PubMedGoogle Scholar
• Bowie CR Leung WW Reichenberg A Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures Biol Psychiatry 2008 63 5 505 511 Epub July 27, 2007 17662256
   PubMed Web of Science ®Google Scholar
• Ishibashi T Horisawa T Tokuda K Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity J Pharmacol Exp Ther 2010 334 1 171 181 20404009
   PubMed Web of Science ®Google Scholar
• Meyer JM Loebel AD Schweizer E Lurasidone: a new drug in development for schizophrenia Expert Opin Investig Drugs 2009 18 11 1715 1726
   PubMed Web of Science ®Google Scholar
• Stahl SM The serotonin-7 receptor as a novel therapeutic target J Clin Psychiatry 2010 71 11 1414 1415 21114946
   PubMed Web of Science ®Google Scholar
• Nakamura M Ogasa M Guarino J Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial J Clin Psychiatry 2009 70 6 829 836 19497249
   PubMed Web of Science ®Google Scholar
• Meltzer HY Cucchiaro J Silva R Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapinecontrolled study Am J Psychiatry 2011 168 9 957 967 21676992
   PubMed Web of Science ®Google Scholar
• Potkin SG Ogasa M Cucchiaro J Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder Schizophr Res 2011 132 2–3 101 107 21889878
   PubMed Web of Science ®Google Scholar
• Kane JM Lurasidone: a clinical overview J Clin Psychiatry 2011 72 Suppl 1 24 28 22217440
   PubMed Web of Science ®Google Scholar
• Citrome L Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic Clin Schizophr Relat Psychoses 2011 4 4 251 257 21177242
   PubMedGoogle Scholar
• Citrome L Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic Int J Clin Pract 2011 65 2 189 210 21129135
   PubMed Web of Science ®Google Scholar
• Roberts AJ Hedlund PB The 5-HT(7) receptor in learning and memory Hippocampus 4 11 2011 [Epub ahead of print.]
   Google Scholar
• Nikiforuk A Selective blockade of 5-HT7 receptors facilitates attentional set-shifting in stressed and control rats Behav Brain Res 2012 226 1 118 123 21925545
   PubMed Web of Science ®Google Scholar
• Ishiyama T Tokuda K Ishibashi T Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test Eur J Pharmacol 2007 572 2–3 160 170 17662268
   PubMed Web of Science ®Google Scholar
• Enomoto T Ishibashi T Tokuda K Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats Behav Brain Res 2008 186 2 197 207 17881065
   PubMed Web of Science ®Google Scholar
• Horiguchi M Huang M Meltzer HY The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats J Pharmacol Exp Ther 2011 338 2 605 614 21558435
   PubMed Web of Science ®Google Scholar
• Meltzer HY Horiguchi M Massey BW The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment Psychopharmacology (Berl) 2011 213 2–3 289 305 21212939
   PubMed Web of Science ®Google Scholar
• Kazuhito Ikeda K Murai T Tsujimura T A unique cognitive enhancing effect of lurasidone in object retrieval with detours, a test of executive function in non-human primates Poster presented at the 40th annual meeting of Society for Neuroscience Nov 2010 San Diego, CA
   Google Scholar
• Horiguchi M Huang M Meltzer HY The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats J Pharmacol Exp Ther 2011 338 2 605 614 21558435
   PubMed Web of Science ®Google Scholar
• Horiguchi M Huang M Meltzer HY Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats Psychopharmacology (Berl) 2011 217 1 13 24 21432027
   PubMed Web of Science ®Google Scholar
• Horisawa T Ishibashi T Nishikawa H The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801- induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone Behav Brain Res 2011 220 1 83 90 21277905
   PubMed Web of Science ®Google Scholar
• Bilder RM Lipschutz-Broch L Reiter G Geisler SH Mayerhoff DI Lieberman JA Intellectual deficits in first-episode schizophrenia: evidence for progressive deterioration Schizophr Bull 1992 18 3 437 448 1411331
   PubMed Web of Science ®Google Scholar
• Klosterkötter J Hellmich M Steinmeyer EM Schultze-Lutter F Diagnosing schizophrenia in the initial prodromal phase Arch Gen Psychiatry 2001 58 2 158 164 11177117
   PubMed Web of Science ®Google Scholar
• Ruhrmann S Schultze-Lutter F Bechdolf A Klosterkötter J Intervention in at-risk states for developing psychosis Eur Arch Psychiatry Clin Neurosci 2010 260 Suppl 2 S90 94 20949359
   PubMed Web of Science ®Google Scholar
• Kaur T Cadenhead KS Treatment implications of the schizophrenia prodrome Curr Top Behav Neurosci 2010 4 97 121 21312398
   PubMedGoogle Scholar
• Horiguchi M Meltzer HY Co-treatment with the atypical antipsychotic drug (APD) lurasidone, or the 5-HT1A agonist, tandospirone, prevents the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in female rats Poster presented at Neuroscience 2011, the 41st Annual Meeting of Society for Neuroscience Nov 2011 Washington DC
   Google Scholar
• Angelucci F Brenè S Mathé AA BDNF in schizophrenia, depression and corresponding animal models Mol Psychiatry 2005 10 4 345 352 15655562
   PubMed Web of Science ®Google Scholar
• Fumagalli F Calabrese F Luoni A Bolis F Racagni G Riva MA Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress Int J Neuropsychopharmacol 2012 15 2 235 246 21349227
   PubMed Web of Science ®Google Scholar
• Luoni A Fumagalli F Calabrese F Ogasa M Racagni G Riva MA Modulation of neurotrophic mechanisms after chronic treatment with the novel antipsychotic lurasidone in rat Poster presented at the 24th European College of Neuropsychopharmacology Congress Sep 2011 Paris, France
   Google Scholar
• Yuen EY Li X Wei J Horiguchi M Meltzer HY Yan Z The novel antipsychotic drug lurasidone enhances NMDA receptor-mediated synaptic responses Mol Pharmacol 2012 81 2 113 119 22072817
   PubMed Web of Science ®Google Scholar
• Potkin SG Silva R Cucchiaro J Metabolomic correlates of response in patients with schizophrenia treated with lurasidone Poster presented at the 164th Annual Meeting of the American Psychiatric Association May 2011 Honolulu, HI
   Google Scholar
• Newman-Tancredi A The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives Curr Opin Investig Drugs 2010 11 7 802 812
   PubMed Web of Science ®Google Scholar
• Guscott M Bristow LJ Hadingham K Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression Neuropharmacology 2005 48 4 492 502 15755477
   PubMed Web of Science ®Google Scholar
• Hedlund PB Huitron-Resendiz S Henriksen SJ Sutcliffe JG 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern Biol Psychiatry 2005 58 10 831 837 16018977
   PubMed Web of Science ®Google Scholar
• Hedlund PB The 5-HT7 receptor and disorders of the nervous system: an overview Psychopharmacology (Berl) 2009 206 3 345 354 19649616
   PubMed Web of Science ®Google Scholar
• Hedlund PB Cates L Roberts AJ Huitron-Resendiz S The antidepressant- like effects of lurasidone are mediated by the 5-HT7 receptor Poster presented at Neuroscience 2011, the 41st Annual Meeting of Society for Neuroscience Nov 2011 Washington DC
   Google Scholar
• Samalin L Garnier M Llorca PM Clinical potential of lurasidone in the management of schizophrenia Ther Clin Risk Manag 2011 7 239 250 21753886
   PubMed Web of Science ®Google Scholar
• Owen RT Lurasidone: a new treatment option for schizophrenia Drugs Today (Barc) 2011 47 11 807 816 22146224
   PubMed Web of Science ®Google Scholar
• Loebel A Cucchiaro J Sarma K Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, Pearl 3 trial Poster presented at the 164th Annual Meeting of the American Psychiatric Association May 2011 Honolulu, HI
   Google Scholar
• Latuda [prescribing information] Marlborough, MA Sunovion Pharmaceuticals 12 2011 Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf Accessed December 20, 2011
   Google Scholar
• Stahl SM Lonnen AJ The mechanism of drug-induced akathsia CNS Spectr 1 15 2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Newcomer JW Pikalov A Cucchiaro J Impact of lurasidone and olanzapine on Framingham ten year coronary heart disease risk estimate in schizophrenia Presented at the 164th Annual Meeting of the American Psychiatric Association May 2011 Honolulu, HI
   Google Scholar
• Keefe RS Bilder RM Davis SM CATIE Investigators; Neurocognitive Working Group Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial Arch Gen Psychiatry 2007 64 633 647 17548746
   PubMed Web of Science ®Google Scholar
• Hill SK Bishop JR Palumbo D Sweeney JA Effect of second-generation antipsychotics on cognition: current issues and future challenges Expert Rev Neurother 2010 10 43 57 20021320
   PubMed Web of Science ®Google Scholar
• Harvey P Siu C Cucchiaro J Pikalov A Maruff P Loebel A Cognitive performance in patients with schizophrenia treated with lurasidone: Results from a placebo and active-controlled acute phase study followed by a 6 month double-blind extension Poster presented at the 50th Annual Meeting of American College of Neuropsychopharmacology Dec 2011 Waikoloa Beach, HI
   Google Scholar
• Green MF What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996 153 3 321 330 8610818
   PubMed Web of Science ®Google Scholar
• Bowie CR Leung WW Reichenberg A Predicting schizophrenia patients’ real-world behavior with specific neuropsychological and functional capacity measures Biol Psychiatry 2008 63 505 551 17662256
   PubMed Web of Science ®Google Scholar
• Harvey PD Lombardi J Leibman M Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades Am J Psychiatry 1997 154 2 205 210 9016269
   PubMed Web of Science ®Google Scholar
• Kurtz MM Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness Expert Rev Neurother 2006 6 1 47 56 16466311
   PubMedGoogle Scholar
• Velligan DI Mahurin RK Diamond PL The functional significance of symptomatology and cognitive function in schizophrenia Schizophr Res 1997 25 1 21 31 9176924
   PubMed Web of Science ®Google Scholar
• Lencz T Smith CW McLaughlin D Generalized and specific neurocognitive deficits in prodromal schizophrenia Biol Psychiatry 2006 59 9 863 871 16325151
   PubMed Web of Science ®Google Scholar
• Knable MB Weinberger DR Dopamine, the prefrontal cortex and schizophrenia J Psychopharmacol 1997 11 123 131 9208376
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS Muly EC3rd Williams GV D(1) receptors in prefrontal cells and circuits Brain Res Brain Res Rev 2000 31 295 301 10719156
   PubMed Web of Science ®Google Scholar
• Davis KL Kahn RS Ko G Davidson M Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 1991 148 1474 1486 1681750
   PubMed Web of Science ®Google Scholar
• Weinberger DR Implications of normal brain development for the pathogenesis of schizophrenia Arch Gen Psychiatry 1987 44 660 669 3606332
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O Dahan L Zimmer L Haddjeri N Effects of the serotonin 5-HT(7) receptor antagonist SB-269970 on the inhibition of dopamine neuronal firing induced by amphetamine Eur J Pharmacol 2007 570 72 76 17586491
   PubMed Web of Science ®Google Scholar
• Cifariello A Pompili A Gasbarri A 5-HT(7) receptors in the modulation of cognitive processes Behav Brain Res 2008 195 1 171 179 18243350
   PubMed Web of Science ®Google Scholar
• Meneses A 5-HT system and cognition Neurosci Biobehav Rev 1999 23 1111 1125 10643820
   PubMed Web of Science ®Google Scholar
• Meneses A A pharmacological analysis of an associative learning task: function of 5-HT1 to 5-HT7 receptor subtypes on a Pavlovian/ instrumental autoshaped memory Learn Mem 2003 10 363 372 14557609
   PubMed Web of Science ®Google Scholar
• Meneses A Manuel-Apolinar L Rocha L Castello E Castello C Expression of the 5-HT receptors in rat brain during memory consolidation Behav Brain Res 2004 152 425 436 15196811
   PubMed Web of Science ®Google Scholar
• Bonaventure P Nepomuceno D Hein L Sutcliffe JG Lovenberg T Hedlund PB Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy- 2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors Neuroscience 2004 4 901 911 15026130
   PubMed Web of Science ®Google Scholar
• Plassat JL Amlaiky N Hen R Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase Mol Pharmacol 1993 2 229 236 8394987
   PubMed Web of Science ®Google Scholar
• Martín-Cora FJ Pazos A Autoradiographic distribution of 5-HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species Br J Pharmacol 2004 1 92 104
   Web of Science ®Google Scholar
• Latuda [prescribing information] Marlborough, MA Sunovion Pharmaceuticals 12 2011 Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf Accessed Dec 20, 2011
   Google Scholar